Ipsen

Ipsen Receivables

The Accounts Receivable of Ipsen (IPN.PA) as of Oct 12, 2026 is 631.30 M EUR. In the previous year, Accounts Receivable was 632.50 M EUR — a change of -0.19% (lower).

Receivables

631.30 MEUR

YoY

-0.19%

Last updated:

Accounts Receivable of Ipsen is 2023 631.30 M EUR. Accounts Receivable of Ipsen was 2022 632.50 M EUR. It decreases by -0.19% lower compared to the previous year.

The Ipsen Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2016
363.50 M EUR
Jan 1, 2017
437.20 M EUR
Jan 1, 2018
463.00 M EUR
Jan 1, 2019
565.00 M EUR
Jan 1, 2020
476.20 M EUR
Jan 1, 2021
564.30 M EUR
Jan 1, 2022
632.50 M EUR
Jan 1, 2023
631.30 M EUR
The Ipsen Receivables history
YEARReceivablesYoY
631.30 MEUR-0.19%
632.50 MEUR+12.09%
564.30 MEUR+18.50%
476.20 MEUR-15.72%
565.00 MEUR+22.03%
463.00 MEUR+5.90%
437.20 MEUR+20.28%
363.50 MEUR+16.88%
311.00 MEUR+27.72%
243.50 MEUR—
Access this data via the Eulerpool API

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

Accounts Receivable of Ipsen is 631.30 M EUR in 2023.

Accounts Receivable of Ipsen changed from 632.50 M EUR to 631.30 M EUR, representing a -0.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Ipsen since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Ipsen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Ipsen

All Key Metrics — Ipsen